| abstract |
In order to provide a low molecular weight compound that has p38MAPK inhibitory activity and the accompanying TNFα production suppression activity and that has a favorable pharmacokinetic profile as a pharmaceutical and decreased hepatotoxicity, and to provide a pharmaceutical application of same, disclosed is a 2,3-dihydro-1H-indene-2-yl urea derivative represented below, a pharmacologically acceptable salt thereof, and a therapeutic agent or preventative agent that contains same as an active ingredient and that is for allergic dermatitis, inflammatory bowel disease, and pain. |